BioLife Solutions, Inc. (BLFS) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows strong financial performance, with a 33% revenue growth in cell processing and improved EBITDA margin. The acquisition of PanTHERA enhances the company's capabilities. Despite increased operating expenses due to acquisition costs, the adjusted operating loss improved. The Q&A section revealed confidence in future revenue, cross-selling opportunities, and product interest. However, the market cap is unavailable, but given the positive trends and strategic positioning, a positive stock price movement (2% to 8%) is anticipated.
Key Financial Performance
Cell Processing Revenue $23 million, a 28% year-over-year increase and up 6% sequentially. The increase was driven by strong performance in the biopreservation media product line, which represents approximately 85% of Q2 cell processing revenue.
Total Revenue $25.4 million, representing an increase of 29% year-over-year. The increase was primarily related to a 28% increase in the cell processing platform.
Adjusted EBITDA Margin 24%, up 400 basis points year-over-year. The improvement was driven by increased sales of biopreservation media and operational leverage.
GAAP Gross Margin 62%, compared with 64% in Q2 2024. The decrease was attributed to fleet repair and maintenance costs at evo operations and a less favorable product mix.
Adjusted Gross Margin 65%, compared with 67% in Q2 2024. The decrease was due to fleet repair and maintenance costs and a less favorable product mix.
GAAP Operating Expenses $42.1 million, versus $21 million in Q2 2024. The increase was largely due to a $15.5 million noncash IPR&D expense from the PanTHERA acquisition and a $1.9 million increase in stock-based compensation.
Adjusted Operating Expenses $16.9 million, compared with $14 million in Q2 2024. The increase was due to higher R&D expenses and operational costs.
GAAP Operating Loss $16.6 million, versus $1.3 million in Q2 2024. The increase was primarily due to the $15.5 million IPR&D expense and higher stock-based compensation.
Adjusted Operating Loss $0.5 million, compared with $0.8 million in Q2 2024. The improvement was due to increased revenue and gross margin.
GAAP Net Loss $15.8 million, or $0.33 per share, compared to $5.6 million, or $0.12 per share, in Q2 2024. The increase was primarily due to the $15.5 million IPR&D expense.
Adjusted EBITDA $6.1 million, or 24% of revenue, compared with $3.9 million, or 20% of revenue, in Q2 2024. The increase was driven by improved gross margin and higher sales of biopreservation media.
Cash and Marketable Securities $100.2 million as of June 30, 2025, compared with $107.6 million as of March 31, 2025. The decrease was due to the $11.5 million PanTHERA acquisition, $2.5 million in debt principal payments, and $1.9 million in capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cell Processing Revenue: Increased 28% year-over-year, driving a 29% increase in total revenue for the quarter. This marks the seventh consecutive quarter of growth in this area.
Biopreservation Media (BPM): Represents 85% of Q2 cell processing revenue, with 60% of BPM revenue coming through direct sales and 40% through distribution. BPM products are embedded in 16 approved therapies and used in over 250 commercially sponsored CGT trials in the U.S.
CellSeal and hPL Products: Utilized in 4 approved therapies and over 35 clinical trials. Potential to increase revenue per dose by 2-3x when integrated into commercial therapy.
Market Share in CGT Trials: BioLife holds over 70% share in U.S. CGT trials, including nearly 80% in Phase III trials, underscoring leadership in late-stage clinical development.
Strategic Investment in Pluristyx: Invested in an early-stage developer of iPSC-based products, aligning with interests in biological assays and portfolio expansion.
Revenue Guidance Increase: Raised full-year cell processing revenue guidance to $91-$93 million, reflecting 24%-26% growth over last year.
Adjusted EBITDA Margin: Expanded by 400 basis points to 24%, driven by strong cell processing performance and operational efficiencies.
Regulatory Developments: FDA's removal of REMS requirement is expected to enhance patient access to cell therapies, streamline workflows, and drive uptake.
Portfolio Expansion: Exploring inorganic growth opportunities, such as the investment in Pluristyx, to expand into relevant adjacencies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Uncertainty: The company acknowledges persistent near-term uncertainties, including tariffs, NIH budget pressures, and ongoing leadership changes at the FDA, which could impact the broader CGT landscape.
Gross Margin Decline: GAAP gross margin decreased from 64% in Q2 2024 to 62% in Q2 2025, and adjusted gross margin decreased from 67% to 65%, attributed to fleet repair and maintenance costs and a less favorable product mix.
Increased Operating Expenses: GAAP operating expenses rose significantly to $42.1 million in Q2 2025 from $21 million in Q2 2024, primarily due to a $15.5 million noncash IPR&D expense and increased stock-based compensation.
Debt Obligations: The company has a $10 million SVB debt balance, with quarterly repayments of $2.5 million and a $1.2 million balloon payment due in June 2026, which could strain cash flow.
Product Mix Challenges: A less favorable product mix as a percentage of revenue contributed to the decline in gross margin, indicating potential challenges in optimizing product portfolio profitability.
Supply Chain and Regulatory Risks: The company is actively monitoring supply chain dynamics and regulatory changes, including tariffs and FDA leadership changes, which could impact operations and financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has raised its full-year revenue guidance to $100 million to $103 million, reflecting an overall growth of 22% to 25%. This is an increase from prior guidance of $95.5 million to $99 million.
Cell Processing Revenue: Cell processing platform revenue is now expected to contribute $91 million to $93 million, reflecting 24% to 26% growth over 2024. This is an increase from prior guidance of $86.5 million to $89 million.
Evo and Thaw Platform Revenue: Revenue from the evo and Thaw platform is expected to contribute $9 million to $10 million, reflecting 3% to 15% growth over 2024. This guidance remains unchanged.
Adjusted Gross Margin: The company expects adjusted gross margin for the full year to be in the mid-60% range.
Adjusted EBITDA Margin: The company anticipates an expansion in adjusted EBITDA margin in 2025 due to higher expected revenue, partially offset by increases in R&D expenses related to development projects.
PanTHERA Revenue: No material revenue is expected from the PanTHERA acquisition in 2025.
Market Trends and Regulatory Developments: The company views the FDA's recent decision to remove the REMS requirement as a positive development for the cell and gene therapy (CGT) landscape, which could enhance patient access, streamline clinical workflows, and drive increased referrals and uptake over time.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the visibility into the 6% ramp in the second half of the year and provide details on commercial ramps or clinical items?
A:Management confirmed the 6% ramp and attributed it to good visibility into the 80% of biopreservation media revenue from the 20 largest customers. They expressed confidence in the second half and full-year numbers, noting potential lumpiness between Q3 and Q4 but no seasonality in the business.
Q:Can you provide updates on the team's focus on cross-selling dynamics and any proof points?
A:Management is tracking cross-selling as a percentage of media customers using other technologies. They are working on reporting metrics and expect to provide updates in Q3. They noted traction with larger accounts, including a significant opportunity with a customer considering the CT-5 automated fill device. They also highlighted progress in understanding clinical trials and targeting customers for cross-selling.
Q:What is the update on the CryoCase timeline and customer feedback?
A:A large commercial customer is interested in adopting CryoCase but requested material changes. Management is seeking a commitment from the customer before proceeding. Over 30 customers are currently evaluating CryoCase.
Q:Do you view PluriFreeze as a competitor, and would acquiring Pluristyx allow market expansion?
A:Management does not see PluriFreeze as a competitive threat, as it focuses on iPSC cells. They are more interested in Pluristyx's assay development capabilities, which align with their strategic interests.
Q:Are there updates on PanTHERA's next-gen combo formulations?
A:Management expects commercial products from PanTHERA in the second half of next year. They are testing one Gen 2 molecule with two customers and anticipate feedback in the next few quarters.
Q:What are your expectations for evo and Thaw, and how does Pluristyx fit into the portfolio?
A:Management is evaluating evo's long-term fit but plans to retain Thaw due to consistent revenue. Pluristyx aligns with their focus on cell processing and assays, which are strategic priorities.
Q:What are the demand trends for early clinical stage customers given funding challenges?
A:Management noted year-over-year growth across all customer segments, with the smallest increase in early-stage clinical customers. They expect this trend to continue.
Q:Is there any change in visibility for the distribution network?
A:Management has not observed any weakness in the distribution network and expects it to remain strong throughout the year.
Q:How does the PanTHERA acquisition advance your portfolio and market share?
A:The acquisition strengthens their market leadership in biopreservation by adding unique IRI characteristics and scientific expertise. They aim to improve cryopreservation efficacy and explore long-term opportunities in cold chain logistics.
Q:What is the rationale behind the $2 million convertible note and M&A strategy?
A:The note provides rights for a potential future acquisition of Pluristyx, contingent on strategic alignment and revenue growth. The M&A strategy focuses on product adjacencies within cell manufacturing and solidifying or achieving market leadership.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the CryoCase customer commitment timeline and the exact metrics for cross-selling dynamics, stating they would provide updates in future quarters.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anna Snopkowski
BPM account
BPM benefit
BPM pharma
BPM portion
BPM product
BioLife Conference
CEO Chairman
FDA
Greef CEO
LLC Research
Research Division
Roderick Greef
Troy Wichterman
Wichterman Chief
access
adjacency
afternoon BioLife
assay
cell processing
cell therapy
change
confidence
core cell
decision
development
increase cell
investment Pluristyx
line cell
potential
processing increase
processing portfolio
product portfolio
product therapy
stage program
visibility
BLFS Transcript
BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call reflects a mixed outlook: declining gross margins due to product mix and manufacturing issues, but a positive net income and ongoing product development. The Q&A highlights potential future benefits from new products and market expansion but also indicates current challenges with margins and no immediate synergies from recent agreements. The guidance for 2026 is cautiously optimistic but lacks strong short-term catalysts, resulting in a neutral sentiment for the stock price.
BioLife Solutions, Inc. (BLFS) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary highlights strong financial performance with a 15% revenue increase and improved gross margins. The company has also raised its revenue guidance, indicating confidence in future growth. Despite the absence of details on operational updates and shareholder returns, the positive financial metrics, increased cash flow, and optimistic guidance suggest a favorable outlook. The lack of concerning insights from the Q&A further supports a positive sentiment.
BioLife Solutions, Inc. (BLFS) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reflects positive sentiment, with raised revenue guidance and improved financial metrics such as GAAP net income and adjusted EBITDA. Despite increased expenses, the company demonstrates strong growth and financial health. The Q&A section supports this with optimistic outlooks for 2026 and no major concerns from analysts. While there are some uncertainties, like the government shutdown, they are already accounted for in the guidance. The focus on growth through commercial customers and the stable funding environment further boosts confidence, indicating a likely positive stock price movement.
BioLife Solutions, Inc. (BLFS) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary shows strong financial performance, with a 33% revenue growth in cell processing and improved EBITDA margin. The acquisition of PanTHERA enhances the company's capabilities. Despite increased operating expenses due to acquisition costs, the adjusted operating loss improved. The Q&A section revealed confidence in future revenue, cross-selling opportunities, and product interest. However, the market cap is unavailable, but given the positive trends and strategic positioning, a positive stock price movement (2% to 8%) is anticipated.
BLFS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
